Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain RARE message board posts where the ticker symbol RARE has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest RARE SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001564590-18-003028 (34 Act)  Size: 214 KB
2018-02-23 001-36276
18636520
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001564590-18-002676 (33 Act)  Size: 134 KB
2018-02-21 333-223124
18628544
S-3ASR  Documents Automatic shelf registration statement of securities of well-known seasoned issuers
Acc-no: 0001193125-18-051916 (33 Act)  Size: 598 KB
2018-02-21 333-223123
18628481
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001564590-18-002663 (34 Act)  Size: 190 KB
2018-02-21 001-36276
18628367
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001564590-18-002535 (34 Act)  Size: 22 MB
2018-02-21 001-36276
18626985
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-18-002472 (34 Act)  Size: 696 KB
2018-02-20 001-36276
18624683
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001073330-18-000005 (34 Act)  Size: 8 KB
2018-02-14 005-87964
18606287
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001422848-18-000357 (34 Act)  Size: 8 KB
2018-02-14 005-87964
18605854
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-001625 (34 Act)  Size: 9 KB
2018-02-13 005-87964
18600159
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-18-003523 (34 Act)  Size: 45 KB
2018-02-09 005-87964
18588542
More RARE SEC Filings


Related news from
Fri, 23 Feb 2018
13:06:38 +0000
See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
Fri, 23 Feb 2018
13:00:00 +0000
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children
Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) today announce that Crysvita (burosumab) has received a positive European Commission decision granting a conditional marketing authorisation to Kyowa Kirin for the treatment of X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. XLH is a rare, chronic progressive musculoskeletal disorder that affects children and adults.
Fri, 23 Feb 2018
13:00:00 +0000
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children
Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease. Crysvita Acknowledged by European Medicines Agency as an Outstanding Contribution to Public Health. TOKYO and LONDON ...
Tue, 20 Feb 2018
22:17:40 +0000
Ultragenyx reports 4Q loss
On a per-share basis, the Novato, California-based company said it had a loss of $1.89. Losses, adjusted for pretax gains, came to $2.27 per share. The results fell short of Wall Street expectations. The ...
Tue, 20 Feb 2018
21:05:00 +0000
Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
NOVATO, Calif., Feb. 20, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results ...
Tue, 20 Feb 2018
17:30:00 +0000
Ultragenyx Pharmaceutical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 20, 2018 at 5:00 ...
Fri, 16 Feb 2018
13:15:00 +0000
Recent Analysis Shows Continental Building Products, Ultragenyx Pharmaceutical, Hilltop, The Blackstone Group, Century Aluminum, and Physicians Realty Trust Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Continental ...
Wed, 14 Feb 2018
21:05:00 +0000
Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
NOVATO, Calif., Feb. 14, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host ...
Wed, 14 Feb 2018
11:19:16 +0000
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE): Does The -26.93% Earnings Decline Make It An Underperformer?
When Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released its most recent earnings update (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarksRead More...
Thu, 08 Feb 2018
13:30:00 +0000
Ultragenyx to Present at Leerink Partners Global Healthcare Conference
NOVATO, Calif., Feb. 08, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, ...
Mon, 29 Jan 2018
13:30:00 +0000
Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President
NOVATO, Calif., Jan. 29, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed ...
Wed, 24 Jan 2018
16:02:31 +0000
Top NasdaqGS High Growth Stock
Ultragenyx Pharmaceutical and ServisFirst Bancshares are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in the futureRead More...
Wed, 24 Jan 2018
13:20:00 +0000
Today’s Research Reports on Trending Tickers: Exact Sciences Corporation and Ultragenyx Pharmaceutical
NEW YORK , NY / ACCESSWIRE / January 24, 2018 / The S&P 500 Index and Nasdaq rose to new records Tuesday on upbeat earnings. The S&P 500 Index gained 0.22 percent to close at a record 2,839.13, while the ...
Wed, 24 Jan 2018
02:40:00 +0000
Ultragenyx Announces Pricing of Public Offering of Common Stock
NOVATO, Calif., Jan. 23, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of ...
Mon, 22 Jan 2018
21:15:00 +0000
Ultragenyx Announces Proposed Public Offering of Common Stock
NOVATO, Calif., Jan. 22, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has commenced ...
Mon, 08 Jan 2018
22:54:10 +0000
Ultragenyx Announces Interim Data from Early Stage Study
Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.
Mon, 08 Jan 2018
19:07:00 +0000
Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - RARE
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
Sun, 07 Jan 2018
16:00:00 +0000
Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 
NOVATO, Cali., Jan. 07, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "At VF I have met some of the greatest givers from all walks of life and from all parts of the world. I thank each of them for sharing part of their life and knowledge with me." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards